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ISSNBackground: Broadly neutralizing antibodies (bNAbs) targeting conserved epitopes on
the HIV envelope glycoprotein have been identified in blood from HIV-1 infected
women. We investigated whether antibodies in the genital tract from these women
share similar epitope specificities and functional profiles as those in blood.
Methods: Immunoglobulin (Ig)G and IgA antibodies were isolated from cervicovaginal
lavages or Softcups from 13 HIV-infected women in the CAPRISA cohort using Protein
G and Peptide M, respectively. Binding antibodies to envelope antigens were quantified
by ELISA and binding antibody multiplex assay. Neutralizing antibody titers and epitope
targets were measured using the TZM-bl assay with Env-pseudotyped wild-type and
mutated viruses.
Results: HIV-specific IgG, but not IgA, was detected in genital secretions and the ratio
of total IgG to HIV-specific IgG was similar to plasma. HIV-specific IgG reacted with
multiple envelope antigens, including V1V2, gp120, gp140 and gp41. Two women had
high plasma titers of HIV-specific IgG3 which was also detected in their genital tract
samples. IgG from the genital tract had neutralizing activity against both Tier 1 and Tier
2 primary HIV-isolates. Antibodies targeting well known glycan epitopes and the
membrane proximal region of gp41 were detected in genital secretions, and matched
specificities in plasma.
Conclusions: Women with plasma bNAbs have overlapping specificities in their
genital secretions, indicating that these predominantly IgG isotype antibodies may
transudate from blood to the genital tract. These data provide evidence that induction of
systemic HIV-specific bNAbs can lead to antiviral immunity at the portal of entry.
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1006 AIDS 2016, Vol 30 No 7neutralizing antibodies (bNAbs) are able to inhibit the
majority of HIV strains and, if elicited by an HIV vaccine,
are likely to be effective at blocking infection at the site of
entry. In non-human primates, passively infused bNAbs
have been shown to inhibit simian-human immunodefi-
ciency virus infection using the high-dose vaginal challenge
model [4–7]. In addition, vaginally applied bNAbs
protected macaques from simian-human immunodefi-
ciency virus vaginal challenge [8,9]. An HIV vaccine may
therefore be required to elicit potent, long-lasting
HIV-specific antibodies in blood and at the genital mucosa,
where the virus is first encountered. In the RV144 human
vaccine trial that showed moderate efficacy, HIV-specific
V1V2 binding antibodies, particularly of the IgG3 subclass,
were found to correlatewith a reduced riskofHIV infection
[10–12]. However, as no mucosal sampling was done in this
vaccine trial, the presence of these potentially protective
antibodies in the genital tract could not be assessed.
HIV-specific binding and neutralizing antibodies have
been described in the genital tract of HIV-infected
women [13–15], and in highly exposed, but persistently
HIV seronegative women [16–18]. HIV-specific anti-
bodies from lower genital tract secretions have been
shown to be predominantly IgG rather than IgA,
suggesting that transudation of systemic HIV-specific
IgG antibodies contributes to IgG dominance at this
mucosal surface [13,19–21]. The neonatal receptor
(FcRn) is involved in IgG transport across polarised
epithelial cells lining mucosal surfaces such as the single-
layered columnar epithelial cells of the endocervical canal,
in a pH-dependent manner [22]. B cells have also been
identified in tissue from the genital tract of HIV-infected
women [23–25], suggesting that there is potentially
also local production of antibodies from resident B cells in
addition to transudation of antibodies from blood.
Natural HIV infection studies have shown that a
proportion of HIV-infected individuals develop bNAbs
in their plasma, generally after many years of infection
[26–30]. The targets of these bNAbs on the HIV
envelope have been mapped to the CD4bs, the glycan at
332, the V1V2 domain, the membrane proximal external
(MPER) region, and the gp120-gp41 interface [31,32].
Approximately 20% of HIV-infected individuals in the
CAPRISA 002 cohort developed plasma bNAbs after
2–4 years of infection [27]. In this study, we investigated
whether HIV-specific bNAbs are present in genital
secretions from these HIV-infected women who devel-
oped breadth systemically, and whether these antibodies
recognized common binding and neutralization epitopes.Methods
Study participants
Plasma and genital secretions collected by cervicovaginal
lavages (CVLs) and/or Softcups were obtained from Copyright © 2016 Wolters Kluwer H13 women in the CAPRISA 002 and CAPRISA 004
cohorts, from Kwa-Zulu Natal, South Africa [33–35]
(Supplementary Table 1, http://links.lww.com/QAD/
A883). This study was approved by the Human Research
Ethics Committees of the University of Witwatersrand,
University of KwaZulu-Natal and University of Cape
Town. All participants provided written informed
consent.
Collection of genital secretions
CVL samples were collected as previously described [36].
Each woman underwent a speculum examination during
which her cervix was irrigated with a lavage of 10 ml
sterile saline. Aspirated saline was transferred to a clean
15 ml tube and centrifuged at 2300 rpm for 10 min
to remove cells. Supernatants were harvested and stored
at 808C. In addition, cervical secretions were collected
using a Softcup Menstrual cup (EuroFemPro, the
Netherlands) and processed as previously described with
modifications [37]. For this, the Softcup was inserted into
the vagina for a minimum of 1 h by a clinician, placed into
a 50 ml tube and centrifuged [38]. The fluid phase was
collected into an eppendorf tube and the volume
measured. The pellet was resuspended and centrifuged
in 300 ml PBS to increase antibody recovery and the fluid
phases combined to a total volume of 500 ml. This was
used for IgG purification on the same day.
Immunoglobulin isolation and quantification
IgG antibodies were isolated using Protein G (Pierce/
Thermo Scientific), whereas IgA was isolated by Peptide
M (InvivoGen) as previously described [39]. The final
fractions were concentrated using 50 000 MW concen-
trators (Millipore). Total IgG and IgA concentrations in
plasma, CVLs and Softcup secretions were quantitated by
ELISA, as previously described [40]. High protein-
binding 96-well microplates (Nalge Nunc International,
Rochester, New York, USA) were coated with 4 mg/ml
goat polyclonal antihuman IgA or IgG (Jackson
ImmunoResearch Laboratories, West Grove, Pennsylva-
nia, USA), and then blocked with 5% goat serum in PBS-
0.05% Tween 20. Duplicates of two-fold serially diluted
samples and a human Immunoglobulin (Ig) reference
serum (Human Immunoglobulin Calibrator; Binding
Site, Birmingham, UK) were added to the plates and
incubated for 1 h at 378C. The captured Ig was detected
after consecutive incubations with biotin-labelled goat
F(ab0)2 specific for human IgA or IgG (BioSource,
Camarillo, California, USA) and horseradish (HRP)-
labelled avidin (Sigma, St. Louis, Missouri, USA). The
ELISA was developed with TMB substrate (Thermo
Fisher Scientific, Rockford, Illinois, USA) and stopped
with a 1 M H2SO4 solution. The plates were read at
450 nm on a microplate reader (Molecular Devices,
Sunnyvale, California, USA). A standard curve was run
on each plate with serial dilutions of a commercial human
IgG (Sigma-Aldrich) or IgA (Jackson Immunoresearch,
Pennsylvania, USA) to calculate antibody concentrations.ealth, Inc. All rights reserved.
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Binding antibodies to HIV proteins and peptides were
measured using a customized HIV binding antibody
multiplex assay (BAMA), as previously described [10,41].
The HIV antigens used included: consensus gp120 Env
(Con6 gp120), clade C gp140 Env trimer (1086 Trimer),
clade C TV1 gp140, Group M consensus gp140 Env
(ConS gp140), clade B gp70 V1V2 fusion protein
(gp70_V1V2), a clade C V1V2 fusion protein
(1086_V1V2), clade B MPER tetramer (MPR.03) and
gp41 (Immunodiagnostics, Woburn, Massachusetts,
USA). Carboxylated fluorescent beads (Luminex Corp.,
Austin, Texas, USA) were covalently coupled to purified
HIV antigens and incubated with clinical samples at
various dilutions. CVL supernatants (not purified for
IgG) were used at a 1 : 5 dilution, whereas plasma
antibodies were measured from a titrated dilution (1 : 100
to 1 : 312 500). HIV-specific total IgG and IgG3 were
detected using PE-conjugated mouse antihuman IgG and
IgG3 (both Southern Biotech, Birmingham, Alabama,
USA), respectively. The beads were washed and acquired
on a Bio-Plex instrument (Bio-Rad) and results expressed
as mean fluorescence intensity (MFI). Responders had
MFI 100 or more. The specific activity (MFIdilution/
antibody concentration) was calculated for genital tract
IgG binding to account for variability in antibody levels
recovered from different women. Responders had
specific activity more than 0.01.
HIV neutralization assays
Neutralization was measured using HIV-Env pseudo-
typed viruses in the TZM-bl assay. Envelope genes were
either cloned previously in our laboratory [42] or
obtained from the NIH AIDS Research and Reference
Reagent Program. This included one Tier 1 virus
(SF162.LS) and three Tier 2 viruses (ConC, CAP45.G3
and TRO.11). Murine leukaemia virus was included in
the assay as a negative control. Neutralization was
measured as a reduction in luciferase gene expression
after a single round of infection in JC53bl-13 cells, also
known as TZM-bl cells, with Env-pseudotyped viruses
[43]. IC50 was calculated as the IgG concentration causing
a 50% reduction of relative light units.
Epitope mapping
For epitope mapping via ELISA, plates were coated with
ConC gp120 proteins or with an MPER peptide
(MPR.03). The ELISA was performed using purified
IgG, as described above. Antibody binding to wild-type
gp120 but not mutant gp120 (containing an N332A
mutation), indicated dependence on the glycan at
position 332. Direct antibody binding to the MPR.03
peptide was used to demonstrate the presence of MPER-
specific IgG. For mapping via neutralization, viruses
containing mutations at key epitopes were used in the
neutralization assay, described earlier. This included
ConC N160A, CAP45.G3 K169E and TRO.11
N332A mutants, used to map bNAb epitopes targeting Copyright © 2016 Wolters Kluwesites in the V2 and V3 regions, shown using monoclonal
antibodies targeting these sites (data not shown). A
reduction in IC50 of the mutant virus compared with the
wild-type virus was used to identify the epitope
specificities of the isolated IgGs.
Statistical analysis
The Mann–Whitney test was used for independent
sample comparisons and a Wilcoxon matched-pairs
signed rank test was performed for dependent sample
comparisons, using GraphPad Prism version 5.0 (Graph-
Pad Software, La Jolla, California, USA). All tests were
two-tailed and P values of less than 0.05 were
considered significant.Results
Higher concentrations of IgG than IgA isotypes
in genital secretions
The quantity of total IgG and IgA antibodies isolated
from matched plasma and genital samples of women,
previously identified as having plasma bNAbs, was
investigated. CVL samples were initially obtained from
seven antiretroviral therapy (ART)-naive women in the
CAPRISA 002 cohort at 3 years postinfection [24]. The
concentration of total IgA was negligible in genital
secretions with a mean value of less than 1 mg/ml,
whereas in plasma the mean value was 359 mg/ml.
Overall, IgG concentrations were 2 logs greater and
significantly higher than IgA concentrations in both
plasma (P¼ 0.016) and CVL (P¼ 0.016) (Fig. 1a).
To determine whether these antibodies were HIV-
specific, we tested them in a gp120 ELISA (Fig. 1b). CVL
IgG antibodies bound gp120 at a median titer of 1 : 34,
whereas the plasma HIV-specific IgG binding titer was
3 logs higher at 1 : 53 697. HIV-specific IgA antibodies in
plasma were detected at a median titer of 1 : 266. None of
the individuals had HIV-specific IgA detected in CVL,
with binding titers at the same level as background. Given
this, we focused the rest of the study on IgG antibodies. In
order to accurately compare HIV-specific IgG concen-
trations in plasma and CVL, we calculated the ratio of
HIV-specific to total IgG. Even though plasma consist-
ently had higher titers of IgG than CVL, the median HIV-
specific activity was similar in CVL and plasma (Fig. 1c).
In order to optimize sample collection for neutralizing
antibody assays, we explored the use of the Softcup for
collecting genital secretions. As this method requires fresh
sample processing, we recruited four of the women with
bNAbs from the CAPRISA 002 cohort who were by
that time on ART, but still had detectable neutralization
titers (Mkhize, unpublished data) along with an additional
six chronically HIV-infected women from the CAPRISA
004 cohort who also developed plasma bNAbsr Health, Inc. All rights reserved.
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Fig. 1. Detection of total and HIV-specific immunoglobulins in the female genital tract. (a) Quantification of immunoglobulin
(Ig)G and IgA concentrations in cervicovaginal lavage (CVL) and plasma of 7 CAPRISA 002 women with broadly neutralizing
activity. (b) gp120-specific binding of IgG and IgA antibodies purified from CVL and plasma. (c) Ratio of total IgG to HIV-specific
IgG concentrations in CVL and plasma from the 7 CAPRISA 002 women, based on 17b mAb standard curve for gp120 IgG. (d)
Comparison of total IgG yields from CVL (from CAPRISA 002) and genital secretions collected using Softcup from 10 women in the
CAPRISA 002 and 004 cohorts.(Madzivhandila, unpublished data). We compared the
yields of total IgG obtained from CVL to those recovered
from the genital tract via the Softcup in all 10 women.
The total IgG recovered from CVL varied amongst
the participants with a range of 0.9–3773 mg/ml, whereas
the total IgG collected via Softcup was more consistent
with a range of 1060–6752 mg/ml (Fig. 1d). Compared
with CVL, the Softcup method resulted in a 13-fold
higher level of total IgG (P¼ 0.003).
HIV-specific antibodies in cervicovaginal lavage
recognize multiple HIV envelope antigens
The kinetics, magnitude, and specificities of antibodies in
CVL and plasma collected from women at 1, 2 and 3 years
postinfection were compared using BAMA. HIV-specific
IgG binding reactivity to all eight HIV Env antigens was
detected in CVLs and plasma, and as there was little
difference between time points, the data were analysed
together (Fig. 2). Antibodies to gp120, gp140, gp41 and
MPER were present at all time points at similar levels in
CVL and plasma. Only antibodies to the V1V2 antigens
differed, with genital tract IgG binding levels significantly
lower than plasma [1086_V1V2 (P¼ 0.0001);
gp70_V1V2 (P¼ 0.0002)]. IgG responses to gp70_V1V2
were better than to 1086_V1V2 and these were detected
in four of seven women at 1 or more time points. Overall,
these data suggest that HIV-specific IgG antibody
specificities in the genital compartment generally match Copyright © 2016 Wolters Kluwer Hthose found in blood plasma, even though levels were
lower in the genital compartment.
Considering the important role of the IgG3 subclass in
HIV-1 vaccine studies [10,11] and bNAbs [44,45], we
further examined this subclass binding response in the
genital compartment. Two individuals, CAP256 and
CAP177, were found to have detectable HIV-specific
IgG3 responses in both plasma and genital compartments
(Fig. 3). For CAP256, plasma IgG3 antibodies to all
antigens remained at high titers over time although
responses to gp70_V1V2 decayed slightly by 3 years
postinfection. Declining responses to all antigens were
also observed in CVL although V1V2 IgG3 responses
were not detected at any time-point. Plasma from
CAP177 contained HIV-specific IgG3 to all antigens
except gp70_V1V2. In this individual, low titers of these
antibodies were also found in the CVL at 1 year
postinfection but declined to below the levels of detection
at later time points. This is likely because of the low
overall concentrations of IgG antibodies recovered from
this participant at the 2- and 3-year time points
(not shown).
HIV-specific neutralizing antibody activity in the
female genital tract
Next, we determined whether HIV-specific antibodies in
CVLs had neutralizing activity. All seven HIV-infectedealth, Inc. All rights reserved.





























































































Fig. 2. HIV-specific activity of immunoglobulin (Ig)G antibodies in cervicovaginal lavage (CVL) and plasma. IgG-binding
antibodies were measured in CVL and plasma from the 7 CAPRISA 002 women who developed broadly neutralizing antibodies.
Dots represent CVL and plasma samples from 1 year (red), 2 years (green) and 3 years (blue) post-HIV infection. Reactivity to eight
antigens was evaluated via the HIV-1 BAMA. The median fluorescence intensity (MFI) values were normalized to total IgG
concentration (specific activity). Samples that had MF1 less than 100 were considered nonresponders and had no values for specific
activity, therefore the points are not reflected on the plots. Responders had a specific activity more than 0.01 for all antigens.women previously shown to have bNAbs [27] had HIV-
specific IgG antibodies that neutralized SF162, an
easy-to-neutralize Tier 1 virus (Fig. 4a). Furthermore,
they also all showed dose-dependent activity against
ConC, a Tier 2 virus, although this did not reach 50%
neutralization in three of seven women. The potent














































































Fig. 3. Immunoglobulin (Ig)G3 binding to HIV-specific antigens. Ig
3 years post-HIV infection. Responses were detected in CAP25
cervicovaginal lavage (left panel) and MFI for plasma samples (rigTier 1 neutralizing antibodies were more prevalent in
CVL, as is also seen in plasma. However, there was a wide
range in IC50 values among these samples with CAP8
showing the highest level of activity against both viruses.
As antibody concentrations were generally low in CVLs,













G3 responses were measured against Env antigens at 1, 2 and
6 (a) and CAP177 (b), represented as specific activity for
ht panel).
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Fig. 4. Neutralization of HIV by purified immunoglobulin (Ig)G from the genital tract. SF162 (Tier 1) and ConC (Tier 2) viruses
were tested in a TZM-bl neutralization assay using IgG isolated from cervicovaginal lavage supernatant (a) and Softcup (b) from
women in the CAPRISA 002 and 004 cohorts. The dotted line represents the IC50.women using cervical Softcups to improve IgG recovery
[38] and allow for more neutralization assays to be
performed (Supplementary Table 1, http://links.lww.
com/QAD/A883). This included two CAPRISA 002
women (CAP8 and CAP248) who were receiving ARTat
the time of Softcup sampling, as well as three additional
women from the CAPRISA 004 cohort who were ART-
naive. Softcup-derived IgGs isolated from five of these
women were able to neutralize both SF162 and ConC
(Fig. 4b). In particular, the ability of all samples to
neutralize ConC with measurable IC50 titers was a
notable improvement over the CVL preparations. This is
despite the fact that some of these women were on ART
that is known to reduce antibody titers [46–48]. Overall,
the IC50 values of the curves suggested that IgG recovered
from the Softcup provided a more consistent preparation
compared with CVL.
Mapping of genital tract IgG antibody
specificities
We previously showed that the plasma bNAbs in CAP177
were dependent on the glycan at position 332 in the V3
region of gp120 [27]. To determine whether genital tract
antibodies shared the same specificity, we used a wild-type
gp120 and an N332A mutant protein that lacked this
glycan, in an ELISA assay. PGT128, a mAb that is highly
dependent on N332 [49] showed significantly less
binding to this mutant protein (data not shown).
Comparison of IgG binding levels revealed a four-fold Copyright © 2016 Wolters Kluwer Hreduction in binding to the mutant protein by IgG from
CVL and a three-fold reduction for plasma IgG (Fig. 5a).
This indicated that a subset of antibodies isolated from the
CVL of CAP177 targeted the N332 glycan epitope on
gp120 similar to the plasma antibodies.
Plasma bNAbs in CAP206 were previously shown to
target the MPER of gp41 and bind the MPR.03 peptide
in an ELISA assay [45,50]. We found that IgG antibodies
isolated from both plasma and CVL of CAP206 bound
the MPR.03 peptide with comparable levels (Fig. 5a)
indicating that antibodies with a similar specificity were
present in both compartments.
We next mapped antibodies by neutralization assay using
epitope-ablating mutants. For this we used the more
abundant IgG collected via Softcup which allowed us to
test multiple mutants (Fig. 5b). For CAP8, purified IgG
antibodies from cervical Softcups and plasma were
sensitive to the N160A mutation in ConC that is
characteristic of many V2-dependent antibodies [51,52].
A V2 antibody was previously isolated from blood of
donor CAP256 that is sensitive to the K169E mutation
[53]. Here we show IgG antibodies from the genital tract
of CAP256 were also sensitive to K169E in the
CAP45.G3 virus. The presence of N332-dependent
antibodies in both genital secretions and plasma from
CAP255 was demonstrated using the TRO.11 virus.
Although the level of neutralization against the wild-typeealth, Inc. All rights reserved.
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Fig. 5. Epitope mapping of antibody specificities by ELISA (a) and neutralization (b). Cervicovaginal lavage and plasma
immunoglobulin (Ig)G antibody specificities in CAP177 at 3 years postinfection were tested by binding to wild-type and N332A
mutant gp120, whereas anti-MPER IgG activity in CAP206 was detected at 3 years postinfection in both genital tract and plasma by
peptide ELISA (a). Plasma and genital tract IgG antibody from CAP8, CAP256 and CAP255 were mapped by measuring
neutralization of wild-type virus and mutant viruses. The dotted lines represent IC50 values (b).virus was less than 50% inhibition (probably because of
low levels of recoverable HIV-specific antibody), there
was almost complete knockout with the N332A mutant.
Overall, these data reliably confirmed the presence of
identical HIV-specific antibody specificities in both
genital secretions and plasma.Discussion
We have detected HIV-specific binding and neutralizing
IgG antibodies in the female genital tract of HIV-infected
women previously shown to have bNAbs in plasma.
Overall, these IgG antibodies matched those in plasma,
targeting major neutralizing antibody epitopes including
V2 and V3 glycans and the MPER of gp41. Binding
antibodies to the V1V2 region, previously shown to
correlate with protection in the RV144 HIV vaccine trial
[12], were also present in the genital tract. The similarity
of the antibody specificities detected in genital secretions
and plasma suggest that the HIV-specific antibodies
(or B cells) are able to transude across the genital mucosa.
This further suggests that antibodies elicited by systemic
vaccination (or transferred through passive immuniz-
ation) are likely to reach mucosal surfaces and could
contribute to preventing the sexual transmission of HIV. Copyright © 2016 Wolters KluweThis study has confirmed earlier reports that HIV-specific
responses in genital secretions are almost exclusively of the
IgG isotype [13,14,21,54]. The paucity of HIV-specific
IgA despite abundant levels of total IgA in lavages of HIV-
infected women has also been noted by others [19,55–
57]. A similar lack of HIV-specific IgA is seen in other
mucosal external secretions including breast milk
although in digestive mucosal secretions, such as saliva
and intestinal surfaces, HIV-specific IgA antibodies
predominate [58–60]. Even though IgG is the dominant
isotype in the genital tract, the levels of total IgG have
been reported to vary during the phases of the menstrual
cycle [61,62]. In this study, sampling of genital secretions
was not normalised according to cycle as our focus was on
examining the functional properties of genital antibodies
which are unlikely to be affected by the menstrual cycle.
Interestingly, HIV-specific IgG could be recovered from
patients on long-term ART indicating that removal of
antigenic stimulation did not ablate the IgG response in
the genital compartment.
Mucosal sampling is particularly challenging for
measuring antibody neutralization because of the low
levels of IgG in genital secretions as well as interfering
components [63]. We therefore isolated and quantified
IgG prior to performing neutralization assays. This
resulted in variable HIV-specific IgG content (the ratior Health, Inc. All rights reserved.
1012 AIDS 2016, Vol 30 No 7of HIV specific IgG to total IgG) probably because large
and variable volumes are recovered by CVL. Antibody
recovery was significantly improved through the use of
the cervical Softcup [64,65], which provided more
consistent data and higher IgG recovery from genital
fluids. The Softcup collects undiluted samples that are
processed immediately [38], and thus are not exposed to
freeze–thaw cycles, which may reduce the concen-
tration of IgG antibodies in CVL [66]. Furthermore,
other studies have shown that the endocervix, which is
more specifically sampled by Softcup, has more
concentrated antibodies than the vagina [60], which
is a washout mainly of the vaginal vault. Another
possible explanation for the improved recovery of
genital IgG is that the Softcup method retains mucus
during processing, which has been shown to harbour
antibodies and other antiviral proteins [67], whereas
during CVL processing mucus is spun down and
discarded. The Softcup thus provides a significant
improvement on CVL sample collection for the analysis
of the humoral immunity to HIV.
The HIV-specific IgG binding activity to most Env
antigens tested was similar for plasma and CVL, except for
V1V2 antigens where lower concentrations of IgG at the
genital tract made it difficult to detect epitope-specific
responses. Although HIV Env-specific IgG reactivity,
which encompasses IgG1–4 isotypes, was observed in all
individuals, only two had detectable IgG3 responses.
These normally short-lived antibodies [68,69] were
detected up to 3 years postinfection in plasma and
CVL. V1V2-specific IgG3 antibodies were shown to
correlate with decreased risk of HIV infection in the
RV144 trial [10–12]. Although we were unable to detect
V1V2 IgG3 at the genital tract, we suspect this is simply
because of lower concentrations in CVL rather than
selective exclusion of these antibodies.
The finding of identical specificities among genital and
plasma neutralizing IgG antibodies strongly supports a
link between the female genital mucosa and blood. This
suggests transudation of antibody from blood across the
genital mucosa; or trafficking of B cells from the
systemic compartment to become resident mucosal
antibody secreting cells [60]. A recent study showed
recruitment of IgG-secreting plasma cells to the genital
tract of vaccinated rhesus macaques as well as a distinct
set of resident cervical reserve epithelial cells that
delivered IgG to the lumen via the neonatal Fc receptor
[70]. The high expression of FcRn reserve cells in the
epithelial layer offers a mechanism by which IgG from
the circulation is transferred to the lumen and genital
tract external surfaces. Several vaccine studies in humans
and primate models have shown HIV or SIV-specific
IgG antibodies in the genital tract [71,72], providing
further evidence of transudation of antibodies either
from the circulation or migration of plasma cells to
the mucosa. Copyright © 2016 Wolters Kluwer HEven though it was not possible to test large panels of
viruses because of limited volumes, this study suggests that
HIV-specific bNAbs are present in the female genital
tract, and overlap in specificity with those present
systemically. This study of women naturally infected with
HIV provides pertinent insight into which plasma-
derived protective antibodies can transude to the genital
tract. Our data suggest that systemic vaccine induced or
passively infused antibodies would migrate to the genital
compartment where they could protect against invading
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